All News

A new legislation signed by Governor Ned Lamont has brought cause for celebration among Connecticut pharmacists and patients alike in the fight for drug pricing transparency.

Insulin levels in the mother's body during fetal development or possible changes to the mother's DNA expression passed to her offspring may increase the risk for developing leukemia.

Merck’s antibacterial drug injection—a combination of imipenem, cilastatin and relebactam (Recarbrio) —is indicated for adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

A Bluetooth-enabled, nanochannel drug delivery system administers controlled doses based on patients’ therapeutic needs.

Top news of the day from across the health care landscape.

Acute flaccid myelitis (AFM) is a rare polio-like condition that can cause limb weakness, and it mostly occurs in young children.

Mergers and acquisitions among health care giants are causing massive disruption in specialty pharmacy.

Top news of the day from across the health care landscape.

Research highlights the importance of reaching non-white and younger populations with skin cancer prevention messages.

Data from the BEACON CRC trial show encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer.

Acetaminophen-related overdose continues to be a leading cause of emergency deparment visits and hospitalizations and remains the leading cause of drug-induced acute liver failure in the United States.

Pre-symptomatic infants with spinal muscular atrophy treated with nusinersen showed continuous improvement in achieving motor milestones.

What caused this eye operation to have complications?

Top news of the day from across the health care landscape.

Which products on the market have the best data?

Pharmacists for Healthier Lives aims to raise awareness around the full range of health care services that pharmacists provide to consumers and patients.

Puma Biotechnology submitted a supplemental New Drug Application to the FDA for neratinib (Nerylnx) in combination with capecitabine for the treatment of patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Study finds elevated risk factors for cardiovascular disease in postmenopausal women with a history of breast cancer.